Observations placeholder
Thorazine and Chlorpromazine
Identifier
001492
Type of Spiritual Experience
A description of the experience
Chlorpromazine – brand names Thorazine; Largactil. Chlorpromazine is a typical antipsychotic. First synthesized in 1950, chlorpromazine was the first drug developed with specific antipsychotic action. In the past, it was used in the treatment of both acute and chronic psychoses, including schizophrenia and the manic phase of bipolar disorder as well as amphetamine-induced psychoses. The use of chlorpromazine and other typical antipsychotics has been largely replaced by newer generation of atypical antipsychotics. It acts as an antagonist (blocking agent) on:
- dopamine receptors (subtypes D1, D2, D3 and D4),
- serotonin receptors (5-HT1 and 5-HT2), with anxiolytic, and anti-aggressive properties, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties
- histamine receptors - H1 receptors, accounting for sedation, antiemetic effect, vertigo, fall in blood pressure and weight gain
- ?1- and ?2-adrenergic receptors - antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction
- M1 and M2 muscarinic acetylcholine receptors - causing anticholinergic symptoms such as dry mouth, blurred vision, constipation, difficulty or inability to urinate, sinus tachycardia, electrocardiographic changes and loss of memory.
Chlorpromazine tends to have greater effect at serotonin receptors than at D2 receptors, which is notably the opposite effect of the other typical antipsychotics. Chlorpromazine and other antipsychotics with sedative properties such as promazine and thioridazine are among the most potent agents at adrenergic receptors. Furthermore, they are also among the most potent antipsychotics at histamine H1 receptors.
On Jan, 25, 2017 439 people reported to have side effects when taking Chlorpromazine Hydrochloride. Among them, 4 people (0.91%) have Hallucination
On Jan, 27, 2017 2,617 people reported to have side effects when taking Thorazine.
Among them, 25 people (0.96%) have Hallucination, Auditory
On Mar, 8, 2015: 2,424 people reported to have side effects when taking Thorazine. Among them, 34 people (1.40%) have Hallucination.
Time on Thorazine when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Thorazine :
| Female | Male | |
| Hallucination | 62.86% | 37.14% |
Age of people who have Hallucination when taking Thorazine :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 3.70% | 3.70% | 33.33% | 37.04% | 3.70% | 18.52% |
On Mar, 7, 2015: 2,424 people reported to have side effects when taking Thorazine. Among them, 63 people (2.60%) have Death.
Time on Thorazine when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 75.00% | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Thorazine :
| Female | Male | |
| Death | 31.75% | 68.25% |
Age of people who have Death when taking Thorazine :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 3.92% | 0.00% | 1.96% | 9.80% | 11.76% | 35.29% | 27.45% | 9.80% |